



(12) Translation of
European patent specification

(11) NO/EP 3683235 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.08.12
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.05.22
(86)	European Application Nr.	20159871.1
(86)	European Filing Date	2014.03.12
(87)	The European Application's Publication Date	2020.07.22
(30)	Priority	2013.03.13, US, 201361778687 P 2013.05.03, US, 201361819018 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(62)	Divided application	EP2970460, 2014.03.12
(73)	Proprietor	Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6706, USA
(72)	Inventor	MURPHY, Andrew, J., 10 Newton Court, Croton-on-Hudson, NY 10520, USA PAPADOPOULOS, Nicholas, J., 59 Heritage Lane, Lagrangeville, NY 12540, USA ORENGO, Jamie, M., 17 Maple Moor Lane, Cortlandt Manor, NY 10567, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **ANTI-IL-33 ANTIBODIES AND USES THEREOF**

(56) References

Cited:

WO-A2-2005/079844
MINGCAI LI ET AL: "IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 247, no. 1, 19 March 2012 (2012-03-19), pages 25-31, XP028486570, ISSN: 0165-5728, DOI: 10.1016/J.JNEUROIM.2012.03.016 [retrieved on 2012-03-25]
FOO Y LIEW ET AL: "Disease-associated functions of IL-33: the new kid in the IL-1 family", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 10, no. 2, 1 February 2010 (2010-02-01), pages 103-110, XP002658775, ISSN: 1474-1741, DOI: 10.1038/NRI2692 [retrieved on 2010-01-18]
Anonymous: "AnaptysBio Announces Development of Novel Anti-IL33 Therapeutic Antibody | AnaptysBio", , 10 January 2014 (2014-01-10), XP055126733, Retrieved from the Internet: URL:<http://www.anaptysbio.com/anti-il33/> [retrieved on 2014-07-03]
PALMER GABY ET AL: "Interleukin-33 biology with potential insights into human diseases", NATURE REVIEWS. RHEUMATOLOGY, NATURE PUBL. GROUP, USA, vol. 7, no. 6, 1 June 2011 (2011-06-01), pages 321-329, XP009178467, ISSN: 1759-4804

H. HAYAKAWA ET AL: "Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, no. 36, 1 January 2007 (2007-01-01), pages 26369-26380, XP055030354, ISSN: 0021-9258, DOI: 10.1074/jbc.M704916200

PALMER G ET AL: "The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 42, no. 3, 1 June 2008 (2008-06-01), pages 358-364, XP022696634, ISSN: 1043-4666, DOI: 10.1016/J.CYTO.2008.03.008 [retrieved on 2008-05-02]

R. KAMEKURA ET AL: "The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis", CLINICAL & EXPERIMENTAL ALLERGY : JOURNAL OF THE BRITISH SOCIETY FOR ALLERGY AND CLINICAL IMMUNOLOGY, vol. 42, no. 2, 1 February 2012 (2012-02-01), pages 218-228, XP055510079, UK ISSN: 0954-7894, DOI: 10.1111/j.1365-2222.2011.03867.x & Anonymous: "Human ST2/IL-33 R Antibody Monoclonal Mouse IgG1 Clone # 97203 Catalog Number: MAB523", , 26 September 2018 (2018-09-26), XP055510080, Retrieved from the Internet: URL:<https://resources.rndsystems.com/pdfs/datasheets/mab523.pdf> [retrieved on 2018-09-26]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Isolert fullstendig humant monoklonalt antistoff eller antigenbindende fragment derav, som spesifikt binder humant interleukin-33 (IL-33), hvor antistoffet eller det antigenbindende fragment omfatter en variabel region av den tunge kjede, som
5 omfatter aminosyresekvensen av SEQ ID NO: 274, og en variabel region av den lette kjede, som omfatter aminosyresekvensen av SEQ ID NO: 282.
2. Humant monoklonalt antistoff ifølge krav 1, som er et IgG1-antistoff.
- 10 3. Humant monoklonalt antistoff ifølge krav 1, som er et IgG4-antistoff.
4. Isolert nukleinsyremolekyl, som koder for et antistoff eller et antigenbindende fragment ifølge et hvilket som helst av kravene 1-3.
- 15 5. Ekspresjonsvektor, som omfatter nukleinsyremolekylet ifølge krav 4.
6. Vertscelle, som omfatter ekspresjonsvektoren ifølge krav 5.
7. Farmasøytisk sammensetning som omfatter antistoffet eller det antigenbindende
20 fragment ifølge et hvilket som helst av kravene 1-3, og en farmasøytisk akseptbar bærer eller fortynner.